Yüklüyor......
Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma—experience at two centres
BACKGROUND: Ramucirumab is a VEGFR-2 antibody that has proven to prolong overall survival (OS) in patients with pretreated metastatic gastric/gastrooesophageal junction (GEJ) adenocarcinoma. We present data from patients treated with ramucirumab and paclitaxel or FOLFIRI after failure of at least on...
Kaydedildi:
| Yayımlandı: | J Gastrointest Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
AME Publishing Company
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7212104/ https://ncbi.nlm.nih.gov/pubmed/32399277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2020.03.10 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|